Septerna (NASDAQ:SEPN) Cut to “Sell” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen downgraded shares of Septerna (NASDAQ:SEPN – Free Report) from a hold rating to a sell rating in a research note published on Saturday.

SEPN has been the topic of a number of other reports. Cantor Fitzgerald upped their target price on shares of Septerna from $20.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, May 16th. HC Wainwright started coverage on shares of Septerna in a report on Monday, June 23rd. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Wells Fargo & Company upped their target price on shares of Septerna from $11.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $26.75.

Get Our Latest Analysis on SEPN

Septerna Trading Down 1.1%

Shares of NASDAQ SEPN opened at $11.59 on Friday. The stock has a market cap of $516.68 million and a price-to-earnings ratio of -1.15. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99. The company’s 50-day moving average price is $11.55 and its 200 day moving average price is $9.07.

Septerna (NASDAQ:SEPN – Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.51). The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. As a group, research analysts expect that Septerna will post -7.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SEPN. JPMorgan Chase & Co. purchased a new position in shares of Septerna during the 4th quarter worth about $871,000. Geode Capital Management LLC purchased a new position in shares of Septerna during the 4th quarter worth about $8,717,000. Wells Fargo & Company MN purchased a new position in shares of Septerna during the 4th quarter worth about $244,000. Invesco Ltd. purchased a new position in shares of Septerna during the 4th quarter worth about $278,000. Finally, Legal & General Group Plc purchased a new position in shares of Septerna during the 4th quarter worth about $42,000.

Septerna Company Profile

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

Read More